Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) obtained approval to export tirzepatide as an active pharmaceutical ingredient (API) to the European Union, according to a Thursday filing with the Shanghai Stock Exchange.
Sinopep-Allsino's factory in Lianyungang passed the EU's good manufacturing practice compliance for export, the filing said.
Tirzepatide is indicated for type 2 diabetes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.